Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-03-18
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of AMG 256 in adult participants and to determine the
maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).